Medios Logo
DE000A1MMCC8
A1MMCC
0QB4.L

Medios

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.


  • Medios exceeds half‑year revenue of €1bn for first time, but lowers EBITDA forecast

    Medios increased revenue in the first half of 2026 by 8.4% to €1.075bn, reaching a half‑year revenue above €1bn for the first time. Despite the revenue growth, EBITDA pre fell 5.1% to €44m and the EBITDA‑pre margin dropped to 4.1%, prompting the company to cut its profit forecast for 2026. Operating cash flow was halved to €11.2m, partly due to timing effects in tax payments. Medios acquired a 74% stake in Caelo for €9.4m and raised its revenue forecast for 2026, but expects continued margin pressure and savings from the Avanti‑Medios! program. » Altro su de.investing.com


  • Medios acquires 74% of Caesar & Loretz and moves into the German active-ingredient market

    Medios is buying 74 percent of Caesar & Loretz GmbH (Caelo), based in Hilden; the transaction is expected to close in the fourth quarter of 2026. Caelo is projected to generate around €40 million in revenue in 2026, roughly 2% of Medios’s planned revenue, but primarily serves as a door opener for entry into the market for pharmaceutical active and auxiliary substances. Medios is likely to consider further internal or external measures to strengthen this area; Q2 figures will be published tomorrow after the profit target for 2026 was already lowered. » Altro su finanzen.net


  • Medios acquires 74 percent of Caelo and confirms annual forecast

    Medios purchases 74 percent of Caesar & Loretz (Caelo); the credit‑financed purchase price is in the upper single‑digit millions and depends on future performance. Caelo expects revenue of around €40 million for 2026 and will be fully consolidated after closing. Completion is subject to market‑standard conditions and is expected in Q4 2026; the takeover has no impact on the annual forecast. Investor reaction: Medios share initially rose by about 1 percent. » Altro su finanzen.net

Nel 2022, Medios ha già distribuito +0,26 di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Medios ha registrato ricavi pari a +547,31M e un utile netto di +3,54M
(EUR) giu 2026
YoY
Ricavi +547,31M 7,94%
Utile lordo +20,11M 12,51%
Utile netto +3,54M 43,75%
EBITDA +19,46M 5,39%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
+270,31M
Numero di azioni
24,80M
Massimo/minimo a 52 settimane
+20,60 - +10,90
Dividendi No
Beta
1,32
Rapporto P/E
+24,77
Rapporto PEG
0,61
Rapporto P/B
+0,51
Rapporto P/S
+0,13

Profilo aziendale

Die Medios AG ist zusammen mit ihren Tochtergesellschaften im Großhandel mit Spezialarzneimitteln in Deutschland tätig. Das Unternehmen ist in den Segmenten Pharmazeutische Versorgung und Patientenspezifische Therapien tätig. Das Segment Pharmazeutische Versorgung bietet Produkte für die Bereiche Onkologie, Neurologie, Autoimmunologie, Augenheilkunde, Infektiologie und Hämophilie an. Das Segment Patientenspezifische Therapien stellt Medikamente für Patienten im Auftrag von Apotheken her und bietet patientenindividuelle Therapien zur Abgabe von individuell dosierten Tabletten an. Das Unternehmen wurde 2016 gegründet und hat seinen Sitz in Berlin, Deutschland.

Nome
Medios
CEO
Thomas Meier
Sede centrale Berlin, be
Germania
Sito web
Settore
Sanità
Industria
Prodotti farmaceutici
Quotazione in borsa
28/12/2007
Dipendenti 982

Simboli di borsa

Borsa Simbolo
London Stock Exchange
0QB4.L
XETRA
ILM1.DE
Pnk
MEDOF
Frankfurt
ILM1.F
Düsseldorf
ILM1.DU
Hamburg
ILM1.HM
London
0QB4.L
SIX
ILM1.SW
München
ILM1.MU
🍪

Parqet  usa i cookie. Scopri di più